{"id":4286,"date":"2022-10-24T19:00:00","date_gmt":"2022-10-25T00:00:00","guid":{"rendered":"https:\/\/shockwavemedical.com\/late-breaking-news-at-viva22-real-world-patients-real-world-results\/"},"modified":"2024-12-09T14:19:02","modified_gmt":"2024-12-09T20:19:02","slug":"late-breaking-news-viva2022","status":"publish","type":"post","link":"https:\/\/shockwavemedical.com\/de\/education\/late-breaking-news-viva2022\/","title":{"rendered":"Late-Breaking News at VIVA22: Real-World Patients, Real-World Results"},"content":{"rendered":"\n<section id=\"block_589d17d69102bb5b21aa1e476c4f6ae5\" class=\"block block--wysiwyg wysiwyg_styles u-bgColorNone container\">\n\t<div class=\"u-wysiwyg u-animation\">\n\t\t<p><span data-contrast=\"auto\">In a late-breaking clinical trial session at VIVA22, Dr. Ehrin Armstrong presented the final 1,373 patient cohort data from the DISRUPT PAD III Observational Study (OS). DISRUPT PAD III OS represents the largest prospective \u2018real-world\u2019 evidence for the treatment of complex, heavily calcified peripheral artery disease. Building on the interim results presented at VIVA21, this larger patient data set reinforces the predictability of IVL and its ability to consistently modify calcium across vessel beds, challenging lesions, and complex patients (CLI, dialysis, and female patients). These real-world outcomes mirror the previously reported DISRUPT PAD III Randomized-Controlled Trial showing that IVL safely and effectively modifies challenging calcium in complex patients.<\/span><span data-ccp-props=\"{\"201341983\":0,\"335559739\":160,\"335559740\":259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Check-out the presentation below and hear from Dr. Armstrong on the importance of the largest prospective \u2018real-world\u2019 data set in the treatment of heavily calcified PAD.<\/span><span data-ccp-props=\"{\"201341983\":0,\"335559739\":160,\"335559740\":259}\">\u00a0<\/span><\/p>\n<div class=\"video\"><iframe title=\"YouTube video player\" data-src=\"https:\/\/www.youtube.com\/embed\/B4RRgb3o2EE?si=r5hNNuoXQhKQcCw5\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" data-load-mode=\"1\"><\/iframe><\/div>\n<div>\n<hr \/>\n<p><span class=\"legal_copy\"> All physicians are paid consultants of Shockwave Medical. <\/span><\/p>\n<p><strong><span class=\"legal_copy\">Important Safety Information<\/span><\/strong><\/p>\n<p><span class=\"legal_copy\"> In the United States: Rx only <\/span><\/p>\n<p><span class=\"legal_copy\">Indications for Use \u2013 The Shockwave Medical Intravascular Lithotripsy (IVL) System is intended for lithotripsy-enhanced balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries.\u00a0 Not for use in the coronary or cerebral vasculature.<\/span><\/p>\n<p><span class=\"legal_copy\"> Contraindications\u00a0\u2013 Do not use if unable to pass 0.014 guidewire across the lesion \u2022 Not intended for treatment of in-stent restenosis or in coronary, carotid, or cerebrovascular arteries. <\/span><\/p>\n<p><span class=\"legal_copy\">Warnings\u00a0\u2013 Only to be used by physicians who are familiar with interventional vascular procedures \u2022 Physicians must be trained prior to use of the device \u2022 Use the Generator in accordance with recommended settings as stated in the Operator\u2019s Manual <\/span><\/p>\n<p><span class=\"legal_copy\">Precautions\u00a0\u2013 Use only the recommended balloon inflation medium \u2022 Appropriate anticoagulant therapy should be administered by the physician \u2022 Decision regarding use of distal protection should be made based on physician assessment of treatment lesion morphology <\/span><\/p>\n<p><span class=\"legal_copy\">Adverse Effects\u00a0\u2013 Possible adverse effects consistent with standard angioplasty include: \u2022 Access site complications \u2022 Allergy to contrast or blood thinners \u2022 Arterial bypass surgery \u2022 Bleeding complications \u2022 Death \u2022 Fracture of guidewire or device \u2022 Hypertension\/Hypotension \u2022 Infection\/sepsis \u2022 Placement of a stent \u2022 Renal failure \u2022 Shock\/pulmonary edema \u2022 Target vessel stenosis or occlusion \u2022 Vascular complications. Risks unique to the device and its use: \u2022 Allergy to catheter material(s) \u2022 Device malfunction or failure \u2022 Excess heat at target site <\/span><\/p>\n<p><span class=\"legal_copy\">Prior to use, please reference the Instructions for Use for more information on indications, contraindications, warnings, precautions, and adverse events.\u00a0<a href=\"http:\/\/www.shockwavemedical.com\">www.shockwavemedical.com <\/a><\/span><\/p>\n<p><span class=\"legal_copy\">Please contact your local Shockwave representative for specific country availability and refer to the Shockwave S4, Shockwave M5 and Shockwave M5+ instructions for use containing important safety information.<\/span><\/p>\n<\/div>\n\t<\/div>\n\t<\/section>","protected":false},"excerpt":{"rendered":"<p>During a late-breaking clinical trial session at VIVA22, Dr. Ehrin Armstrong presented the final 1,373 patient cohort data from the Disrupt PAD III OS.<\/p>\n","protected":false},"author":2,"featured_media":11470,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":[207,210],"meta":{"_acf_changed":true,"content-type":"","footnotes":""},"categories":[3],"tags":[],"disease-state":[169],"education-topic":[185,189],"product-tag":[285],"specialty":[330,346],"technology":[326],"class_list":["post-4286","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-unkategorisiert","disease-state-peripheral-artery-disease-de","education-topic-best-practices-de","education-topic-case-reviews-de","format-article-de","format-video-de","product-tag-shockwave-m5-de","specialty-interventional-cardiologists-de","specialty-vascular-surgeons-de","technology-peripheral-ivl-de"],"acf":[],"_links":{"self":[{"href":"https:\/\/shockwavemedical.com\/de\/wp-json\/wp\/v2\/posts\/4286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/shockwavemedical.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/shockwavemedical.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/shockwavemedical.com\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/shockwavemedical.com\/de\/wp-json\/wp\/v2\/comments?post=4286"}],"version-history":[{"count":0,"href":"https:\/\/shockwavemedical.com\/de\/wp-json\/wp\/v2\/posts\/4286\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/shockwavemedical.com\/de\/wp-json\/wp\/v2\/media\/11470"}],"wp:attachment":[{"href":"https:\/\/shockwavemedical.com\/de\/wp-json\/wp\/v2\/media?parent=4286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/shockwavemedical.com\/de\/wp-json\/wp\/v2\/categories?post=4286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/shockwavemedical.com\/de\/wp-json\/wp\/v2\/tags?post=4286"},{"taxonomy":"disease-state","embeddable":true,"href":"https:\/\/shockwavemedical.com\/de\/wp-json\/wp\/v2\/disease-state?post=4286"},{"taxonomy":"education-topic","embeddable":true,"href":"https:\/\/shockwavemedical.com\/de\/wp-json\/wp\/v2\/education-topic?post=4286"},{"taxonomy":"format","embeddable":true,"href":"https:\/\/shockwavemedical.com\/de\/wp-json\/wp\/v2\/format?post=4286"},{"taxonomy":"product-tag","embeddable":true,"href":"https:\/\/shockwavemedical.com\/de\/wp-json\/wp\/v2\/product-tag?post=4286"},{"taxonomy":"specialty","embeddable":true,"href":"https:\/\/shockwavemedical.com\/de\/wp-json\/wp\/v2\/specialty?post=4286"},{"taxonomy":"technology","embeddable":true,"href":"https:\/\/shockwavemedical.com\/de\/wp-json\/wp\/v2\/technology?post=4286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}